News
MLLCF
2.550
NaN%
--
Clear Street transfers coverage on Molecular Partners, keeps Buy rating
TipRanks · 4d ago
Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating
TipRanks · 08/25 20:15
Molecular Partners doses first patients in MP0317 combination study
TipRanks · 07/16 09:41
LifeSci Capital Sticks to Their Buy Rating for Molecular Partners (MOLN)
TipRanks · 07/11 14:35
Molecular Partners Reaffirmed at Buy as Analyst Cites MP0712 Progress and Keeps $12 Price Target Unchanged
TipRanks · 07/02 10:45
Molecular Partners, Orano Med doses first patient in MP0712 study
TipRanks · 07/02 09:25
Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study
TipRanks · 05/31 20:30
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
TipRanks · 05/12 23:15
Molecular Partners publishes MP0317 clinical data in Nature Cancer
TipRanks · 05/01 11:32
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
TipRanks · 04/22 10:25
Molecular Partners announces presentation of preclinical data at AACR
TipRanks · 04/19 16:55
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
TipRanks · 03/16 10:26
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
TipRanks · 03/16 05:45
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
TipRanks · 03/13 16:15
Molecular Partners (MOLN) Gets a Buy from Clear Street
TipRanks · 03/13 11:19
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
TipRanks · 02/26 21:45
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
TipRanks · 02/26 10:45
Molecular Partners presents first imaging, dosimetry data of MP0712
TipRanks · 02/02 10:30
Molecular Partners initiated with a Buy at H.C. Wainwright
TipRanks · 01/27 11:11
Molecular Partners (MOLN) Gets a Buy from LifeSci Capital
TipRanks · 01/20 13:38
More
Webull provides a variety of real-time MLLCF stock news. You can receive the latest news about Molecular Partnr through multiple platforms. This information may help you make smarter investment decisions.
About MLLCF
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.